Selection, design, and engineering of therapeutic antibodies

被引：54

作者：

Presta, LG ^{[1
]}

机构：

[1] Schering Plough Biopharma, Palo Alto, CA 94304 USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2005年 / 116卷 / 04期

关键词：

antibody engineering; target selection; biologic therapeutics;

D O I：

10.1016/j.jaci.2005.08.003

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

mAbs account for an increasing portion of marketed human biological therapeutics. As a consequence, the importance of optimal selection, design, and engineering of these not only has expanded in the past 2 decades but also is now coming into play as a competitive factor. This review delineates the 4 basic areas for optimal therapeutic antibody selection and provides examples of the increasing number of considerations necessary for, and options available for, antibody design. Though some of the advances in antibody technology (eg, antibodies derived from phage-display libraries) have already made it to market, other more recent advances, such as engineering antibodies for enhanced effector functions, may not be far behind, especially given the increasing competition for therapeutic antibodies to the same target (eg, anti-CD20 and anti-TNF-alpha).

引用

页码：731 / 736

页数：6

共 52 条

[1]

Adams GP, 2001, CANCER RES, V61, P4750

[2] A SINGLE AMINO-ACID SUBSTITUTION ABOLISHES THE HETEROGENEITY OF CHIMERIC MOUSE/HUMAN (IGG4) ANTIBODY [J].